Faculty
Cynthia Ma.jpg

Cynthia X. Ma, MD, PhD

Associate Professor
Department of Medicine
Oncology Division
Medical Oncology

Clinical Interests

  • Breast cancer

Research Interests

  • Pharmacogenomics of anticancer agents
  • Predictive biomarkers
  • Developmental therapeutics

Contact

  • 314-362-9383 (tel)
  • 314-362-7086 (fax)
  • 4515 McKinley Research Building, Room 3311 (office)
  • Division of Oncology
    Campus Box 8076
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Invited Publications

  • Treating and managing future risk in women with hereditary breast cancer
    Ma CX
    Cancer News in Context, July 13, 2016
  • Palbociclib in hormone-receptor-positive advanced breast cancer
    Hernandez-Aya LF, Ma CX
    Breast Diseases: A Year Book Quarterly. 2016
  • Chemotherapy principles of managing stage IV breast cancer in the United States
    Hernandez-Aya LF, Ma CX
    Chin Clin Oncol 2016 Jun;5(3):42
  • Prognostic and predictive biomarkers of endocrine responsiveness for estrogen receptor positive breast cancer
    Ma CX, Bose R, Ellis MJ
    Adv Exp Med Biol 2016;882:125-54
  • Improving response to hormone therapy in breast cancer: new targets, new therapeutic options
    Rugo HS, Vidula N, Ma C
    Am Soc Clin Oncol Educ Book 2016;35:e40-54
  • Breast Cancer, Chapter 24
    Ademuyiwa F, Bose R, Ma CX
    In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology Review, 4e
  • Neratinib in early-stage HER2-positive breast cancer
    Cherian MA, Ma CX
    Breast Diseases: A Year Book Quarterly. 2015 December
  • DCIS: time to change our standard of care?
    Ma CX
    Oncology Times 2015 August
  • Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer
    Nagaraj G, Ma C
    Breast Cancer Res Treat 2015 Apr;150(2):231-42
  • The PI3K pathway as a therapeutic target in breast cancer
    Ma CX
    American Journal of Hematology/Oncology. 2015 March
  • Mechanisms of aromatase inhibitor resistance
    Ma CX, Reinert T, Chmielewska I, Ellis MJ
    Nat Rev Cancer 2015 Apr 24;15(5):261-75
  • Key breast cancer takeaways from ASCO 2015
    Ma CX
    Oncology Times 2015 June 29
  • Key breast cancer takeaways from asco 2014
    Ma CX
    Oncology Times 2014 June 29
  • Chapter 14: Breast cancer
    Ademuyiwa F, Suresh R, Ellis MJ, Ma CX
    In: Washington Manual of Oncology 4th Edition, Lippincott Williams & Wilkens 2014
  • Metastatic breast cancer: best practices based on cancer subtypes
    Ma CX
    Young Women’s Breast Cancer Program in St. Louis Magazine. 2014
  • Best breast cancer research 2013
    Ma CX
    Oncology Times 2014 Jan 24
  • The Cancer Genome Atlas: clinical applications for breast cancer
    Ma CX, Ellis MJ
    Oncology (Williston Park) 2013 Dec;27(12):1263-9, 1274-9
  • Incorporating genomics into breast cancer clinical trials and care
    Tabchy A, Ma CX, Bose R, Ellis MJ
    Clin Cancer Res 2013 Dec 1;19(23):6371-9
  • Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer
    Ademuyiwa FO, Ellis MJ, Ma CX
    J Oncol 2013;2013:219869
  • Chapter 19: Genomic events in breast cancer progression
    Goncalves R, Cakar B, Bose R, Ma CX, Ellis MJ
    In: Disease of the Breast, 5th Edition
  • Targeted therapy for breast cancer
    Mohamed A, Krajewski K, Cakar B, Ma CX
    Am J Pathol 2013 Oct;183(4):1096-112
  • PI3K inhibitors in breast cancer treatment
    Pacheco JM, Ma CX
    The International Journal of Targeted Therapies in Cancer 2013 May 7
  • Biology of breast cancer - better therapy promised for triple negative breast cancer
    Ma CX
    Oncology Times 2013 Jan 6
  • Mammalian target of rapamycin inhibitors in breast cancer therapy CML
    Ezewuiro O, Ma CX, Fleming GF
    Breast Cancer 2012;24(4):117–30
  • The natural history of hormone receptor-positive breast cancer: attempting to decipher an intriguing concept
    Nagaraj G, Ellis MJ, Ma CX
    Oncology (Williston Park) 2012 Aug;26(8):696-7, 700
  • Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies
    Roop RP, Ma CX
    Future Oncol 2012 Mar;8(3):273-92
  • Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
    Goncalves R, Ma C, Luo J, Suman V, Ellis MJ
    Nat Rev Clin Oncol 2012 Feb 28;9(4):223-9
  • Molecular basis of triple negative breast cancer and implications for therapy
    Peddi PF, Ellis MJ, Ma C
    Int J Breast Cancer 2012;2012:217185
  • PARP inhibitors and their evolving role in breast cancer
    Roop RP, Ma CX, Ellis MJ
    Oncology (Williston Park) 2011 Oct;25(11):1033-4
  • Estrogen and progesterone receptors in breast cancer
    Ma CX
    Clin Adv Hematol Oncol 2011 May;9(5):385-6
  • Systemic therapy for metastatic breast cancer: endocrine therapy (online chapter)
    Ellis M, Hayes D, Naughton M, Ma CX
    UpToDate 19.2 2011
  • Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors
    Ma CX, Crowder RJ, Ellis MJ
    Steroids 2011 Jul;76(8):750-2
  • Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
    Ma CX, Janetka JW, Piwnica-Worms H
    Trends Mol Med 2011 Feb;17(2):88-96
  • Optimal selection of adjuvant chemotherapy in patients with breast cancer (chapter)
    Ma CX
    Epocrates 2010
  • Molecular profiling of triple negative breast cancer
    Ma CX, Luo J, Ellis MJ
    Breast Dis 2010 Jan 1;32(1):73-84
  • Hedgehog pathway inhibitors: potential applications in breast cancer (review)
    Chia YH, Ma CX
    Current Breast Cancer Report 2010;3(1):15-23
  • Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool
    Chia YH, Ellis MJ, Ma CX
    Br J Cancer 2010 Sep 7;103(6):759-64
  • Commentary on "Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Research 70 (1):319-28"
    Ma CX, Ellis MJ
    Breast Diseases: A Year Book Quarterly 2010;21(3):266-7
  • Neoadjuvant endocrine therapy for breast cancer
    Chawla JS, Ma CX, Ellis MJ
    Surg Oncol Clin N Am 2010 Jul;19(3):627-638
  • Updates on adjuvant trastuzumab therapy for breast cancer
    Ma CX
    China Medical Tribute B4-B5 2010 March 18; B4-B5
  • Commentary on "Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361(8):766-76"
    Chia YH, Ma CX, Ellis MJ
    Breast Diseases: A Year Book Quarterly 2010;21(2):168-9
  • Neoadjuvant endocrine therapy for breast cancer
    Chia YH, Ma CX, Ellis MJ
    Breast Diseases: A Year Book Quarterly 2009;20(4):355-7
  • Commentary on "Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99:1763-8"
    Chia YH, Ma CX
    Breast Diseases: A Year Book Quarterly 2009;20(3):327-8
  • Commentary on "Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor–positive, advanced breast cancer: results from EFECT. J Clin Oncol 26:1664-70"
    Chia YH, Ma CX
    Breast Diseases: A Year Book Quarterly 2009;20(1):94-5
  • An update on adjuvant therapy with trastuzumab, part 3
    Chia YH, Ma CX
    E-Updates in HER2 Targeting in Breast Cancer 2009; 3
  • An update on the use of lapatinib, part 3
    Ma CX, Chia YH
    E-Updates in HER2 Targeting in Breast Cancer 2009; 3
  • Predicting endocrine therapy responsiveness in breast cancer
    Ma CX, Sanchez CG, Ellis MJ
    Oncology (Williston Park) 2009 Feb;23(2):133-42
  • Letrozole in the neoadjuvant setting: the P024 trial
    Ellis MJ, Ma C
    Breast Cancer Res Treat 2007;105 Suppl 1:33-43
  • Femara and the future: tailoring treatment and combination therapies with Femara
    Ellis M, Ma C
    Breast Cancer Res Treat 2007;105 Suppl 1:105-15
  • Commentary on "A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer, Clinical Cancer Research 11 (13): 4741-8"
    Ma CX, Ellis MJ
    Breast Diseases, A Year Book Quarterly 2006;17(3):282-3
  • Neoadjuvant endocrine therapy for locally advanced breast cancer
    Ma CX, Ellis MJ
    Semin Oncol 2006 Dec;33(6):650-6
  • Endocrine therapy resistance: molecular predictive models and mechanism-based solutions
    Ma CX, Ellis MJ
    Translating advances in hormonal therapies for breast cancer into clinical practice: a continuing education monograph for oncology professionals by Meniscus, Aug 2006: pp 25-34